{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:09:45Z","timestamp":1780456185147,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T00:00:00Z","timestamp":1484092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T00:00:00Z","timestamp":1484092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00535-016-1303-0","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T09:48:09Z","timestamp":1484128089000},"page":"855-867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3847-1065","authenticated-orcid":false,"given":"Seiichi","family":"Mawatari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Tabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Ijuin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Uto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Hiramine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Oshige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Imanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Saishoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oki","family":"Taniyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Sakae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Moriuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Ido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,11]]},"reference":[{"key":"1303_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000252782","volume":"53","author":"H Chung","year":"2010","unstructured":"Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50\u00a0years in Japan. Intervirology. 2010;53:39\u201343.","journal-title":"Intervirology"},{"key":"1303_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jhep.2011.07.016","volume":"56","author":"H Kumada","year":"2012","unstructured":"Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78\u201384.","journal-title":"J Hepatol"},{"key":"1303_CR3","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1111\/j.1365-2893.2011.01528.x","volume":"19","author":"N Hayashi","year":"2012","unstructured":"Hayashi N, Okanoue T, Tsubouchi H, et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19:e134\u201342.","journal-title":"J Viral Hepat"},{"key":"1303_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jhep.2014.04.004","volume":"61","author":"N Hayashi","year":"2014","unstructured":"Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon\/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014;61:219\u201327.","journal-title":"J Hepatol"},{"key":"1303_CR5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00535-014-0949-8","volume":"49","author":"N Izumi","year":"2014","unstructured":"Izumi N, Hayashi N, Kumada H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014;49:941\u201353.","journal-title":"J Gastroenterol"},{"key":"1303_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/hepr.12375","volume":"45","author":"H Kumada","year":"2015","unstructured":"Kumada H, Hayashi N, Izumi N, et al. Simeprevir (TMC435) once daily with peginterferon-alpha-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: the CONCERTO-4 study. Hepatol Res. 2015;45:501\u201313.","journal-title":"Hepatol Res."},{"key":"1303_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00535-014-0979-2","volume":"50","author":"N Hayashi","year":"2015","unstructured":"Hayashi N, Mobashery N, Izumi N. Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study. J Gastroenterol. 2015;50:238\u201348.","journal-title":"J Gastroenterol"},{"key":"1303_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00535-012-0714-9","volume":"48","author":"K Chayama","year":"2013","unstructured":"Chayama K, Hayes CN, Ohishi W, et al. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 2013;48:1\u201312.","journal-title":"J Gastroenterol"},{"key":"1303_CR9","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083\u201391.","journal-title":"Hepatology"},{"key":"1303_CR10","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:1597\u2013605.","journal-title":"Lancet"},{"key":"1303_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/hep.22339","volume":"48","author":"A El-Shamy","year":"2008","unstructured":"El-Shamy A, Nagano-Fujii M, Sasase N, et al. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon\/ribavirin combination therapy. Hepatology. 2008;48:38\u201347.","journal-title":"Hepatology"},{"key":"1303_CR12","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jcv.2012.04.024","volume":"54","author":"F Suzuki","year":"2012","unstructured":"Suzuki F, Sezaki H, Akuta N, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol. 2012;54:352\u20134.","journal-title":"J Clin Virol"},{"key":"1303_CR13","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1128\/JCM.39.11.3858-3864.2001","volume":"39","author":"MI Lusida","year":"2001","unstructured":"Lusida MI, Nagano-Fujii M, Nidom CA, et al. Correlation between mutations in the interferon sensitivity-determining region of NS5A protein and viral load of hepatitis C virus subtypes 1b, 1c, and 2a. J Clin Microbiol. 2001;39:3858\u201364.","journal-title":"J Clin Microbiol"},{"key":"1303_CR14","doi-asserted-by":"publisher","first-page":"11658","DOI":"10.1128\/JVI.00995-07","volume":"81","author":"T Kuntzen","year":"2007","unstructured":"Kuntzen T, Timm J, Berical A, et al. Viral sequence evolution in acute hepatitis C virus infection. J Virol. 2007;81:11658\u201368.","journal-title":"J Virol"},{"key":"1303_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","volume":"138","author":"C Sarrazin","year":"2010","unstructured":"Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138:447\u201362.","journal-title":"Gastroenterology"},{"key":"1303_CR16","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1128\/AAC.00556-10","volume":"54","author":"RA Fridell","year":"2010","unstructured":"Fridell RA, Qiu D, Wang C, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54:3641\u201350.","journal-title":"Antimicrob Agents Chemother"},{"key":"1303_CR17","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/hep.24594","volume":"54","author":"RA Fridell","year":"2011","unstructured":"Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology. 2011;54:1924\u201335.","journal-title":"Hepatology"},{"key":"1303_CR18","doi-asserted-by":"publisher","unstructured":"Iio E, Shimada N, Abe H, et al. Efficacy of daclatasvir\/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. J Gastroenterol. 2016. doi:10.1007\/s00535-016-1225-x.","DOI":"10.1007\/s00535-016-1225-x"},{"key":"1303_CR19","unstructured":"http:\/\/www.jsh.or.jp\/medical\/guidelines\/jsh_guidlines\/hepatitis_c."},{"key":"1303_CR20","doi-asserted-by":"publisher","unstructured":"Uchida Y, Kouyama JI, Naiki K, et al. Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir\/asunaprevir therapy by a two-hit mechanism. Hepatol Res. 2016. doi:10.1111\/hepr.12673.","DOI":"10.1111\/hepr.12673"},{"key":"1303_CR21","doi-asserted-by":"publisher","first-page":"E115","DOI":"10.1111\/hepr.12474","volume":"45","author":"J Itakura","year":"2015","unstructured":"Itakura J, Kurosaki M, Takada H, et al. Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy. Hepatol Res. 2015;45:E115\u201321.","journal-title":"Hepatol Res."},{"key":"1303_CR22","unstructured":"AbbVie. (Pharmaceutical Interview form of Viekirax). AbbVie. 2016. http:\/\/www.abbvie.co.jp\/content\/dam\/abbviecorp\/japan\/docs\/if_Viekirax_j.pdf."},{"key":"1303_CR23","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/jmv.24360","volume":"88","author":"N Akuta","year":"2016","unstructured":"Akuta N, Sezaki H, Suzuki F, et al. Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. J Med Virol. 2016;88:506\u201311.","journal-title":"J Med Virol"},{"key":"1303_CR24","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-\u03b1 and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105\u20139.","journal-title":"Nat Genet"},{"key":"1303_CR25","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-\u03b1 and ribavirin therapy. Nat Genet. 2009;41:1100\u20134.","journal-title":"Nat Genet"},{"key":"1303_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/jmv.20507","volume":"78","author":"N Akuta","year":"2006","unstructured":"Akuta N, Suzuki F, Sezaki H, et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol. 2006;78:83\u201390.","journal-title":"J Med Virol"},{"key":"1303_CR27","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/hep.25826","volume":"56","author":"S Maekawa","year":"2012","unstructured":"Maekawa S, Sakamoto M, Miura M, et al. Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection. Hepatology. 2012;56:1611\u201321.","journal-title":"Hepatology"},{"key":"1303_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1056\/NEJM199601113340203","volume":"334","author":"N Enomoto","year":"1996","unstructured":"Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334:77\u201381.","journal-title":"N Engl J Med"},{"key":"1303_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jhep.2010.07.037","volume":"54","author":"M Kurosaki","year":"2011","unstructured":"Kurosaki M, Tanaka Y, Nishida N, et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol. 2011;54:439\u201348.","journal-title":"J Hepatol"},{"key":"1303_CR30","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/j.1478-3231.2010.02283.x","volume":"30","author":"T Asselah","year":"2010","unstructured":"Asselah T, Estrabaud E, Bieche I, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010;30:1259\u201369.","journal-title":"Liver Int"},{"key":"1303_CR31","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/hep.28446","volume":"63","author":"F Poordad","year":"2016","unstructured":"Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63:1493\u2013505.","journal-title":"Hepatology"},{"issue":"602\u20138","key":"1303_CR32","first-page":"e1","volume":"9","author":"T Reiberger","year":"2011","unstructured":"Reiberger T, Rutter K, Ferlitsch A, et al. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol. 2011;9(602\u20138):e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1303_CR33","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1053\/jhep.2003.50207","volume":"37","author":"C Liu","year":"2003","unstructured":"Liu C, Zhu H, Tu Z, et al. CD8+ T-cell interaction with HCV replicon cells: evidence for both cytokine- and cell-mediated antiviral activity. Hepatology. 2003;37:1335\u201342.","journal-title":"Hepatology"},{"key":"1303_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hep.27922","volume":"62","author":"V Saxena","year":"2015","unstructured":"Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of simeprevir\/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology. 2015;62:715\u201325.","journal-title":"Hepatology"},{"key":"1303_CR35","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","volume":"15","author":"M Mizokami","year":"2015","unstructured":"Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12\u00a0weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15:645\u201353.","journal-title":"Lancet Infect Dis"},{"key":"1303_CR36","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1002\/hep.27724","volume":"61","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology. 2015;61:1798\u2013808.","journal-title":"Hepatology"},{"issue":"501\u201312","key":"1303_CR37","first-page":"e1","volume":"151","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151(501\u201312):e1.","journal-title":"Gastroenterology"},{"key":"1303_CR38","doi-asserted-by":"publisher","first-page":"e0130022","DOI":"10.1371\/journal.pone.0130022","volume":"10","author":"S Yoshimi","year":"2015","unstructured":"Yoshimi S, Ochi H, Murakami E, et al. Rapid, sensitive, and accurate evaluation of drug resistant mutant (NS5A-Y93H) strain frequency in genotype 1b HCV by Invader assay. PLoS ONE. 2015;10:e0130022.","journal-title":"PLoS ONE"},{"key":"1303_CR39","doi-asserted-by":"publisher","first-page":"e112647","DOI":"10.1371\/journal.pone.0112647","volume":"9","author":"Y Uchida","year":"2014","unstructured":"Uchida Y, Kouyama J, Naiki K, et al. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS ONE. 2014;9:e112647.","journal-title":"PLoS ONE"},{"key":"1303_CR40","doi-asserted-by":"publisher","first-page":"E360","DOI":"10.1111\/hepr.12316","volume":"44","author":"M Miura","year":"2014","unstructured":"Miura M, Maekawa S, Sato M, et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res. 2014;44:E360\u20137.","journal-title":"Hepatol Res"},{"key":"1303_CR41","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s12325-016-0354-1","volume":"33","author":"D Hernandez","year":"2016","unstructured":"Hernandez D, Yu F, Huang X, et al. Impact of pre-existing NS5A-L31 or -Y93H minor variants on response rates in patients Infected with HCV genotype-1b treated with daclatasvir\/asunaprevir. Adv Ther. 2016;33:1169\u201379.","journal-title":"Adv Ther"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-016-1303-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1303-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1303-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:52:19Z","timestamp":1659055939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-016-1303-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,11]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["1303"],"URL":"https:\/\/doi.org\/10.1007\/s00535-016-1303-0","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,11]]},"assertion":[{"value":"5 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}